CL2016002020A1 - Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor - Google Patents

Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Info

Publication number: CL2016002020A1
Authority: CL; Chile
Prior art keywords: plp; cofactor; erythrocytes; encapsulate; envelope
Prior art date: 2014-02-12

Application number

CL2016002020A

Other languages

English (en)

Inventor

Yann Godfrin

Vanessa Bourgeaux

Fabien Gay

Thomas Cortese

Original Assignee

Erytech Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-12

Filing date

2016-08-10

Publication date

2017-06-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-08-10 Application filed by Erytech Pharma filed Critical Erytech Pharma

2017-06-23 Publication of CL2016002020A1 publication Critical patent/CL2016002020A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01005—Tyrosine transaminase (2.6.1.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Developmental Biology & Embryology (AREA)
Botany (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)

CL2016002020A 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor CL2016002020A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1451100A FR3017299B1 (fr)	2014-02-12	2014-02-12	Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur

Publications (1)

Publication Number	Publication Date
CL2016002020A1 true CL2016002020A1 (es)	2017-06-23

Family

ID=50729647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2016002020A CL2016002020A1 (es)	2014-02-12	2016-08-10	Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Country Status (17)

Country	Link
US (3)	US10046009B2 (es)
EP (2)	EP3104875B1 (es)
JP (1)	JP6563958B2 (es)
KR (1)	KR102354103B1 (es)
CN (2)	CN111358941B (es)
AU (2)	AU2015217045B2 (es)
BR (1)	BR112016017337B1 (es)
CA (1)	CA2938469C (es)
CL (1)	CL2016002020A1 (es)
ES (1)	ES2808849T3 (es)
FR (1)	FR3017299B1 (es)
IL (1)	IL246941B (es)
JO (1)	JO3522B1 (es)
MX (1)	MX378781B (es)
RU (2)	RU2697086C2 (es)
SG (2)	SG11201606264SA (es)
WO (1)	WO2015121348A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015073587A2 (en)	2013-11-18	2015-05-21	Rubius Therapeutics, Inc.	Synthetic membrane-receiver complexes
FR3017299B1 (fr)	2014-02-12	2018-05-18	Erytech Pharma	Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
PL3125927T3 (pl)	2014-04-01	2021-07-19	Rubius Therapeutics, Inc.	Sposoby i kompozycje do immunomodulacji
EP3187190A1 (en)	2015-12-31	2017-07-05	Erytech Pharma	Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
EA201891606A1 (ru)	2016-01-11	2019-02-28	Эписентарикс, Инк.	Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
AU2017207738A1 (en)	2016-01-11	2018-07-12	Rubius Therapeutics, Inc.	Compositions and methods related to multimodal therapeutic cell systems for cancer indications
BR112018074716A2 (pt)	2016-06-02	2019-03-12	Sanofi	conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose
SG11201914046WA (en)	2017-07-07	2020-01-30	Epicentrx Inc	Compositions for parenteral administration of therapeutic agents
EP3449935A1 (en) *	2017-08-31	2019-03-06	Erytech Pharma	Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
JP7176921B2 (ja)	2017-10-19	2022-11-22	アンチキャンサーインコーポレーテッド	癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤
JP2021504402A (ja)	2017-12-01	2021-02-15	サノフイＳａｎｏｆｉ	薬剤とグルコース感知タンパク質に結合し得る部分との新規のコンジュゲート
US11510901B2 (en)	2018-01-08	2022-11-29	Epicentrx, Inc.	Methods and compositions utilizing RRx-001 combination therapy for radioprotection
US11541105B2 (en)	2018-06-01	2023-01-03	The Research Foundation For The State University Of New York	Compositions and methods for disrupting biofilm formation and maintenance
US20210403571A1 (en)	2018-11-15	2021-12-30	Erytech Pharma	Synergistic combinations of methionine depletion agents and immune checkpoint modulators
JP2022530130A (ja)	2019-04-26	2022-06-27	ルビウスセラピューティクス，インコーポレイテッド	除核赤血球細胞を含む緩衝組成物
SG11202111995TA (en)	2019-05-24	2021-12-30	Rubius Therapeutics Inc	Methods of generating enucleated erythroid cells
JP2023500325A (ja)	2019-11-04	2023-01-05	ルビウスセラピューティクス，インコーポレイテッド	タウリンまたはヒポタウリンを使用して除核赤芽球細胞を生成する方法
CN115038784A (zh)	2019-11-04	2022-09-09	鲁比厄斯治疗法股份有限公司	使用肌-肌醇产生去核红系细胞的方法
CA3178252A1 (en)	2020-05-11	2021-11-18	Erytech Pharma	Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2022150569A1 (en)	2021-01-08	2022-07-14	Rubius Therapeutics, Inc.	METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
TW202241470A (zh)	2021-01-08	2022-11-01	美商盧比亞斯治療公司	治療人類個體腫瘤之方法
TW202304482A (zh)	2021-03-14	2023-02-01	美商盧比亞斯治療公司	於個體中增加nkg2d陽性淋巴球之方法及其用途
WO2022246126A1 (en) *	2021-05-21	2022-11-24	Codexis, Inc.	Engineered methionine gamma lyase variants
TW202317179A (zh)	2021-06-03	2023-05-01	美商盧比亞斯治療公司	在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
CN113481253B (zh) *	2021-06-09	2022-05-24	连云港杰瑞药业有限公司	生物催化制备磷酸吡哆醛的方法
WO2023067200A1 (en)	2021-10-24	2023-04-27	Erytech Pharma	Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2025219395A1 (en)	2024-04-16	2025-10-23	Chu D'angers	Treatment of cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1354204A (fr)	1963-01-22	1964-03-06	Auxiliaire De L Entpr Soc	Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière
FR2529463B1 (fr) *	1982-07-05	1986-01-10	Centre Nat Rech Scient	Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5254572A (en) *	1987-11-27	1993-10-19	Vesta Medicines (Pty) Ltd.	Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) *	1986-11-29	1997-05-20	Serfontein; Willem J.	Methods and preparations for the treatment and prophylaxis of metabolic disturbances
JP3811863B2 (ja)	1997-03-13	2006-08-23	塩野義製薬株式会社	Ｌ−メチオニン γ−リアーゼ結晶の製造方法
WO2002029040A2 (en) *	2000-10-06	2002-04-11	Millennium Pharmaceuticals, Inc.	25219, a novel human aminotransferase and uses therefor
EP1664326A2 (en) *	2003-07-31	2006-06-07	Anticancer, Inc.	The use of plp with peg-rmetase in vivo for enhanced efficacy
FR2873925B1 (fr)	2004-08-05	2006-10-13	Erytech Pharma Soc Par Actions	Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr)	2005-04-25	2009-07-03	Erytech Pharma Soc Par Actions	Erythrocytes renfermant de l'arginine deiminase
RU2362572C2 (ru) *	2007-07-17	2009-07-27	Юрий Георгиевич Каминский	Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
FR2919804B1 (fr)	2007-08-08	2010-08-27	Erytech Pharma	Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr)	2007-12-24	2010-03-05	Erytech Pharma	Medicament pour le traitement du cancer du pancreas
US20100316620A1 (en)	2008-02-13	2010-12-16	Vanessa Bourgeaux	Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
FR2928270B1 (fr)	2008-03-10	2011-01-21	Erytech Pharma	Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr)	2008-11-07	2011-11-25	Erytech Pharma	Test predictif de la neutralisation de l'activite asparaginase
CN101429506A (zh) *	2008-12-15	2009-05-13	吉林大学	基于红细胞载体的fish-in-net固定化酶
FR2944106B1 (fr)	2009-04-03	2012-09-28	Erytech Pharma	Methode de dosage de l'inositol hexaphosphate (ihp).
PT2493487T (pt)	2009-10-27	2016-11-08	Erytech Pharma	Composição para induzir uma tolerância imunitária específica
WO2013139906A1 (en) *	2012-03-21	2013-09-26	Erytech Pharma	Medicament for the treatment of acute myeloid leukemia (aml)
FR3005420B1 (fr)	2013-05-07	2015-09-18	Erytech Pharma	Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP2813234A1 (en)	2013-06-11	2014-12-17	Erytech Pharma	Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (fr)	2014-02-12	2018-05-18	Erytech Pharma	Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) *	2015-12-31	2017-07-05	Erytech Pharma	Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

2014
- 2014-02-12 FR FR1451100A patent/FR3017299B1/fr not_active Expired - Fee Related
2015
- 2015-02-12 EP EP15705563.3A patent/EP3104875B1/en active Active
- 2015-02-12 CN CN202010182496.4A patent/CN111358941B/zh active Active
- 2015-02-12 JO JOP/2015/0030A patent/JO3522B1/ar active
- 2015-02-12 RU RU2016133315A patent/RU2697086C2/ru active
- 2015-02-12 KR KR1020167022067A patent/KR102354103B1/ko not_active Expired - Fee Related
- 2015-02-12 CA CA2938469A patent/CA2938469C/en active Active
- 2015-02-12 WO PCT/EP2015/052962 patent/WO2015121348A2/en not_active Ceased
- 2015-02-12 US US15/117,588 patent/US10046009B2/en active Active
- 2015-02-12 EP EP20173043.9A patent/EP3718562A1/en not_active Withdrawn
- 2015-02-12 RU RU2019123935A patent/RU2744659C2/ru active
- 2015-02-12 MX MX2016010235A patent/MX378781B/es unknown
- 2015-02-12 SG SG11201606264SA patent/SG11201606264SA/en unknown
- 2015-02-12 SG SG10201907367QA patent/SG10201907367QA/en unknown
- 2015-02-12 BR BR112016017337-6A patent/BR112016017337B1/pt not_active IP Right Cessation
- 2015-02-12 CN CN201580007812.1A patent/CN106255506B/zh not_active Expired - Fee Related
- 2015-02-12 JP JP2016568136A patent/JP6563958B2/ja not_active Expired - Fee Related
- 2015-02-12 ES ES15705563T patent/ES2808849T3/es active Active
- 2015-02-12 AU AU2015217045A patent/AU2015217045B2/en not_active Ceased
2016
- 2016-07-25 IL IL246941A patent/IL246941B/en active IP Right Grant
- 2016-08-10 CL CL2016002020A patent/CL2016002020A1/es unknown
2018
- 2018-02-21 AU AU2018201237A patent/AU2018201237B2/en not_active Ceased
- 2018-08-13 US US16/102,171 patent/US10780126B2/en active Active
2020
- 2020-09-22 US US17/028,383 patent/US11458170B2/en active Active

Also Published As

Publication number	Publication date
US10046009B2 (en)	2018-08-14
JO3522B1 (ar)	2020-07-05
MX378781B (es)	2025-03-11
US10780126B2 (en)	2020-09-22
CA2938469A1 (en)	2015-08-20
US20180344771A1 (en)	2018-12-06
CN106255506A (zh)	2016-12-21
US20160361361A1 (en)	2016-12-15
ES2808849T3 (es)	2021-03-02
CA2938469C (en)	2023-03-14
EP3104875B1 (en)	2020-05-06
CN111358941B (zh)	2023-12-01
BR112016017337B1 (pt)	2022-08-09
EP3718562A1 (en)	2020-10-07
KR102354103B1 (ko)	2022-01-24
IL246941A0 (en)	2016-09-29
WO2015121348A3 (en)	2015-10-08
RU2016133315A (ru)	2018-02-16
RU2016133315A3 (es)	2018-09-26
EP3104875A2 (en)	2016-12-21
AU2018201237B2 (en)	2019-09-26
US11458170B2 (en)	2022-10-04
FR3017299B1 (fr)	2018-05-18
RU2697086C2 (ru)	2019-08-12
MX2016010235A (es)	2016-10-28
JP2017506260A (ja)	2017-03-02
IL246941B (en)	2019-09-26
SG11201606264SA (en)	2016-08-30
SG10201907367QA (en)	2019-09-27
FR3017299A1 (fr)	2015-08-14
RU2744659C2 (ru)	2021-03-12
AU2015217045B2 (en)	2018-03-08
WO2015121348A2 (en)	2015-08-20
CN111358941A (zh)	2020-07-03
KR20160121532A (ko)	2016-10-19
CN106255506B (zh)	2020-04-14
BR112016017337A2 (es)	2017-08-08
AU2015217045A1 (en)	2016-08-18
RU2019123935A3 (es)	2020-03-26
JP6563958B2 (ja)	2019-08-21
AU2018201237A1 (en)	2018-03-15
RU2019123935A (ru)	2019-10-03
US20210008114A1 (en)	2021-01-14

Publication	Publication Date	Title
CL2016002020A1 (es)	2017-06-23	Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor
IL258931A (en)	2018-06-28	Therapeutic compounds and methods
EP3447085A4 (en)	2019-08-21	CELLULOSIC RESIN COMPOSITION AND CELLULOSE COMPONENT
PL3423105T3 (pl)	2021-10-25	Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
EP3436482A4 (en)	2020-03-11	ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
HUE053619T2 (hu)	2021-07-28	Anti-CD123 antitestek és konjugátumok és ezek származékai
ES2715251R1 (es)	2019-11-28	Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina
EP3500255A4 (en)	2020-03-25	PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE
EP3355847A4 (en)	2019-07-03	ASEPTIC COMPOSITION OF PHARMACEUTICAL CONTAINERS
EP3341007A4 (en)	2019-05-01	MALT1 INHIBITORS AND USES THEREOF
EP3434285A4 (en)	2019-10-30	PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
BR112017016465A2 (pt)	2018-06-19	composto heterocíclico e composição farmacêutica que o compreende
EP3463345A4 (en)	2020-02-26	PHARMACEUTICAL COMBINATIONS
EP3405044A4 (en)	2019-02-27	BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF
BR112016028188A2 (pt)	2018-06-26	embalagens e método de fabricação da mesma
FI20155027A7 (fi)	2016-07-15	Polymyksiinijohdannainen ja sen käytöt
PT3320903T (pt)	2021-08-19	Composição farmacêutica contendo amlodipina, valsartan e rosuvastatina
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
PL3145508T3 (pl)	2023-10-23	Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
EP2994197A4 (en)	2016-12-28	PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
FI20145984A7 (fi)	2016-05-11	Substituoitua bentsofurokinolitsiinia ja ɑ2-adrenergista agonistia käsittävät koostumukset
IL248629A0 (en)	2017-01-31	Cycloalkyl-linked diheterocycle derivatives
EP3302513A4 (en)	2019-01-23	COMPOSITION AND USES THEREOF
FI20155009A7 (fi)	2016-07-10	Pakkausaihio ja pakkaus
EP3302483A4 (en)	2019-02-27	PHARMACEUTICAL COMPOSITIONS AND USE THEREOF